Close Menu

NEW YORK – The US Food and Drug Administration has created a new pathway for Emergency Use Authorization of serology tests for SARS-CoV-2.

Dubbed an "umbrella" pathway for serology, it entails submitting tests for evaluation to an interagency testing group, with that evaluation currently being done at the National Cancer Institute, Timothy Stenzel, director of the US Food and Drug Administration's Office of In Vitro Diagnostics and Radiological Health, said during a Wednesday conference call for test developers.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.